CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. Between 75-95% of retail investor accounts lose money when trading CFDs with this provider. You should consider whether you understand how CFDs work and whether you can afford to take the high risk of losing your money.
Open platformOpen platform

QuidelOrtho Q3 revenue misses estimates on soft respiratory season

By Reuters News


Overview

  • US diagnostics provider's Q3 revenue fell 12% yr/yr, missing analyst expectations

  • Adjusted diluted EPS for Q3 was $0.31


Outlook

  • Company sees 2026 total revenue between $2.52 bln and $2.54 bln

  • QuidelOrtho expects 2026 adjusted EBITDA of $540 mln to $545 mln

  • Company forecasts 2026 adjusted diluted EPS of $0.65 to $0.70


Result Drivers

  • CHINA IMPACT - Co said lower Labs sales in China, tied to changes in In Vitro Diagnostics pricing, weighed on results

  • SOFT RESPIRATORY SEASON - Co attributed decline in Point of Care revenue to weaker respiratory season

  • RESTRUCTURING PROGRAM - Co launched cost transformation and restructuring program aimed at improving profitability


Company press release:


Key Details

Metric

Beat/Miss

Actual

Consensus Estimate

Q3 Revenue

Miss

$618.9 mln

$628.13 mln (3 Analysts)

Q3 Loss Per Share

$0.78

Q3 Net Loss

$53.8 mln

Q3 Loss Per Basic Share

$0.78

Q3 Operating Income

-$7.5 mln


Analyst Coverage

  • The current average analyst rating on the shares is "hold" and the breakdown of recommendations is 1 "strong buy" or "buy", 1 "hold" and 1 "sell" or "strong sell"

  • The average consensus recommendation for the advanced medical equipment & technology peer group is "buy."

  • Wall Street's median 12-month price target for QuidelOrtho Corp is $16.00, about 14% above its November 2 closing price of $14.03

  • The stock recently traded at 11 times the next 12-month earnings vs. a P/E of 8 three months ago


Reuters Recommended Reads

  • Nov 2 - IDEXX Laboratories Q3 revenue beats estimates, lifts FY profit outlook

  • Nov 3 - Revvity Q3 revenue beats estimates, raises FY guidance

  • Nov 3 - SOPHiA GENETICS Q3 revenue rises on US market strength


For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.


(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)

Capital.com is an execution-only brokerage platform and the content provided on the Capital.com website is intended for informational purposes only and should not be regarded as an offer to sell or a solicitation of an offer to buy the products or securities to which it applies. No representation or warranty is given as to the accuracy or completeness of the information provided.

The information provided does not constitute investment advice nor take into account the individual financial circumstances or objectives of any investor. Any information that may be provided relating to past performance is not a reliable indicator of future results or performance.

To the extent permitted by law, in no event shall Capital.com (or any affiliate or employee) have any liability for any loss arising from the use of the information provided. Any person acting on the information does so entirely at their own risk.

Any information which could be construed as “investment research” has not been prepared in accordance with legal requirements designed to promote the independence of investment research and as such is considered to be a marketing communication.